Ann: Investor Webinar Presentation, page-64

Thanks—I really enjoyed your post too.

They’ve definitely signalled interest in doing a deal. OncoSil’s been open to partnerships, licensing, or even a potential acquisition for a while now. Nigel touched on it in the Feb 2025 webinar—said discussions are ongoing, just couldn’t share anything specific yet. And as you know, they also brought in Kidder Williams a couple of years back. The last mention I recall was from Otto Buttula in the 2023 Annual Report, saying they “continue to have dialogue with cornerstone partners through our corporate advisers Kidder Williams.” So while nothing’s landed yet, it’s pretty clear there’s interest.

The idea of an Asian strategic partner isn’t far-fetched. With Kidder Williams' connections and the clear need for a solution like OncoSil in markets like China, it feels like a logical next step—especially if Europe keeps proving the model. That said, it’s not clear if Kidder Williams are still formally engaged, but it wouldn’t surprise me if history repeated itself.